10th week of 2010 patent applcation highlights part 36 |
Patent application number | Title | Published |
20100062012 | Negative Genetic Regulation of Cancer Cell Renewal in Synergy with Notch- or Numb-Specific Immunotherapy - We disclose a method of treating a cancer in a patient by immunizing the patient against a peptide derived from a protein selected from the group consisting of Notch 1, Notch2, Notch3, and Notch4. We further disclose a composition containing a peptide as described above and a pharmaceutically-acceptable carrier. In addition, we disclose a method of treating a cancer in a patient by immunizing the patient against a peptide derived from a protein selected from the group consisting of Numb1, Numb2, Numb3, and Numb4. We also disclose a composition containing a peptide as described above and a pharmaceutically-acceptable carrier. Further, we disclose a method of treating a cancer in a patient by administering to the patient a composition comprising an antibody against a peptide derived from a protein selected from the group consisting of Notch 1, Notch2, Notch3, Notch4, Numb1, Numb2, Numb3, and Numb4. | 2010-03-11 |
20100062013 | CANCER ANTIGEN PEPTIDES DERIVED FROM WT1 - The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding said peptide, CTL-inducers, and cancer vaccine comprising said peptide or polynucleotide. | 2010-03-11 |
20100062014 | H3 EQUINE INFLUENZA A VIRUS - The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof. | 2010-03-11 |
20100062015 | FUSION PROTEIN VACCINE - The present invention relates to the fields of microbiology and vaccine technology, and concerns the development of a vaccine capable of conferring immunity to group B | 2010-03-11 |
20100062016 | Microorganisms for therapy - Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proferating proliferating tissues, particularly tumors, to produce selected proteins and other products. Vaccines containing the microorganisms are provided. Combinations of the microorganisms and anti-cancer agents and uses thereof for treating cancer also are provided. | 2010-03-11 |
20100062017 | Pasteurella multocida vaccine - The present invention relates to live attenuated bacteria of the species | 2010-03-11 |
20100062018 | MYCOPLASMA HYOPNEUMONIAE BACTERIN VACCINE - The invention provides an improved | 2010-03-11 |
20100062019 | NEW VACCINE FORMULATIONS - The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof. In one embodiment, the present invention provides for an injectable oil-in-water (O/W) emulsion comprising:
| 2010-03-11 |
20100062020 | Method of Treating a Malignancy in a Subject Via Direct Picornaviral-Mediated Oncolysis - There are provided methods for treatment of abnormal cells such as cancer cells in a mammal. The methods involve treating the mammal with virus selected from echoviruses and modified forms and combination thereof, which recognize α | 2010-03-11 |
20100062021 | VACCINATION FOR LAWSONIA INTRACELLULARIS - The present invention include a method of protecting an animal against | 2010-03-11 |
20100062022 | IMMUNOGENIC PROTEINS OF BURKHOLDERIA PSEUDOMALLEI AND USES THEREOF - A protein derived from an outer layer of | 2010-03-11 |
20100062023 | CHOLESTEROL-CONTAINING COMPOUNDS AND THEIR USE AS IMMUNOGENS AGAINST BORRELIA BURGDORFERI - Unique compounds that can be used for inducing an immune response to | 2010-03-11 |
20100062024 | Biologically Active Hemagglutinin From Type A Clostridium Botulinum and Methods of Use - An isolated, biologically active 33 kDa hemagglutinin purified from the type A | 2010-03-11 |
20100062025 | Use of Clostridium perfringens type C bacterium for the manufacture of a vaccine - The present invention relates to the use of a vaccine comprising | 2010-03-11 |
20100062026 | POLY TLR ANTAGONIST - w or its components are found to have poly TLR antagonistic activity to induced TLRs by varieties of TLR ligands. The induced TLR against which inhibitory effect is seen includes TLR 3, 4, 5, 6, 7, 8, 9. They also display antagonistic activities to effects of TLR ligands. They are also useful in management of diseases wherein TLRs are over expressed, like sepsis, multiple sclerosis, optic neuritis, Chronic obstructive pulmonary diseases multiple myeloma etc. | 2010-03-11 |
20100062027 | INTERACTION OF MORAXELLA CATARRHALIS WITH EPITHELIAL CELLS, EXTRACELLULAR MATRIX PROTEINS AND THE COMPLEMENT SYSTEM - The present invention relates to surface proteins of | 2010-03-11 |
20100062028 | VACCINES FOR MALARIA - The present invention relates to a novel hybrid/fusion protein derived from the CS protein of | 2010-03-11 |
20100062029 | Product for the Targeted Release of Active Substances - The invention relates to a product for the targeted release of active substances, especially detergents and/or cosmetic active substances. The inventive product has a layer structure, one layer being impermeable to the active substance and another layer being permeable to the active substance. The two layers define a compartment between them which contains the active substance and optionally a gas-releasing component. The product is preferably suitable for single use and can be used as a cosmetic agent and/or as a cleaning agent. | 2010-03-11 |
20100062030 | USE OF DIACETYL DIMER AS AN AROMATIC AND/OR FLAVOURING SUBSTANCE - The invention relates to the use of 5-acetyl-2,5-dimethyl-2-hydroxy-tetrahydrofuran-3-one (diacetyl dimer of formula (I)) in the form of one of its stereoisomers or in the form of a mixture consisting of or containing two, three or four of its stereoisomers | 2010-03-11 |
20100062031 | ANTIBACTERIAL SHEET AND ABSORBENT ARTICLE - Disclosed is an antibacterial sheet including an antibacterial composition and a sheet-like base member with the antibacterial composition attached thereto. In the antibacterial sheet, a composition including an antibacterial agent and a water-soluble thermoplastic polymer which is solid at a normal temperature and which dissolves in a body fluid is used as the antibacterial composition. | 2010-03-11 |
20100062032 | Doped Titanium Dioxide Coatings and Methods of Forming Doped Titanium Dioxide Coatings - Methods for forming doped titanium dioxide coatings are disclosed. Sol-gel compositions are prepared having at least one dopant, are formed on a substrate, and heated at a temperature sufficient to form a doped anatase titanium dioxide coating. Doped titanium dioxide coatings having at least one of improved antimicrobial properties, self-cleaning properties, hydrophilicity, and/or activation time are also disclosed. Substrates comprising such coatings are also disclosed. | 2010-03-11 |
20100062033 | Stable Silver Colloids and Silica-Coated Silver Colloids, and Methods of Preparing Stable Silver Colloids and Silica-Coated Silver Colloids - Methods for preparing silver colloids and silica-coated silver colloids are disclosed. The silver colloids may be prepared by heating a silver-containing solution, combining the heated silver-containing solution with an acid solution, and cooling the combined solutions to form a silver colloid containing silver particles. The silver particles in the silver colloid can further be coated with silica. A method for preparing antimicrobial coatings is also disclosed. | 2010-03-11 |
20100062034 | MEMBRANE SHELL OF AN IMPLANTABLE DOSAGE SYSTEM - The membrane shell of an implantable dosage system according to the invention is particularly suitable for subcutaneous applications to release an active agent with steady amounts during a longer period of time. The membrane shell ( | 2010-03-11 |
20100062035 | Biocompatible Antimicrobial Filament Material - The invention provides a biocompatible filament material having an antimicrobial finish, in particular in the form of a surficial layer, the finish comprising polyhexamethylenebiguanide (PHMB) as a nonspecifically antimicrobially active component, and also a process for producing the filament material, comprising the steps of:
| 2010-03-11 |
20100062036 | Multiblock Copolymers with Shape-Memory Properties - The invention is directed to a multiblock copolymer with shape memory properties and a synthetic precursor of the multiblock copolymer 1. The multiblock copolymer contains: (i) a poly(depsipeptide) segment with an average molecular weight M | 2010-03-11 |
20100062037 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME - Subcutaneous implants obtained by extrusion containing an active ingredient dispersed in a PLGA matrix obtained by grinding an extruded product consisting of a blend of: at least two PLGA having different lactic acid/glycolic acid molar ratios and different weight average molecular weights, or a PLGA and PLA having different weight average molecular weight. | 2010-03-11 |
20100062038 | Markers, Antibodies and Recombinant scFvs for Mesenchymal Stem Cell Sub-populations and Osteoclasts - Abstract Markers, antibodies and recombinant scFvs for Mesenchymal Stem Cell sub-populations and osteoclasts. The present invention relates to specific epitopes of surface membrane bound glycoproteins expressed by mesenchymal stem cells and pre-osteoclasts and relates to antibodies such as monoclonal antibodies and recombinant scFv or fragments thereof, raised to the particular epitope and their use in identifying, isolating, and characterization of mesenchymal stem cell sub-populations such as that termed “Stromal Progenitor Cells” (SPCs) in bone marrow and identifying, isolating, and characterization of pre-osteoclasts in peripheral blood. By binding to a specific epitope on the cell surface, limbin/EVC-2 detection and separation by conventional cell sorting methodologies are facilitated. | 2010-03-11 |
20100062039 | Intravaginal Ringed Mesh Device And Applicator Therefor - This invention generally covers a ringed-mesh intravaginal device and applicator therefore wherein the ringed-mesh comprises a composite ring comprising a flexible matrix containing one or more bioactive agent or agents and needed excipients or modulators, and the said matrix is reinforced with a fibrous construct to provided needed initial and in-use biomechanical stability. Of special application of the medicated, ringed-mesh is its use for securing contraception relying on biomechanical, pharmacological, and biochemical means. | 2010-03-11 |
20100062040 | WATER SOLUBLE DRUGS AND SUPPLEMENTS - A method of forming water soluble microparticles is disclosed that includes the steps of providing a water insoluble food supplement, mixing the food supplement in a water miscible polar solvent, heating the mixture to increase the solubility and dissolve the food supplement into the solvent to form a saturated solution, and streaming the solution into water to form a solvent-water mix such that microparticles of the food supplement are produced | 2010-03-11 |
20100062041 | SKIN SUNSTITUTES, PREPARATION METHODS AND USES THEREOF - Provided herein are skin substitutes suitable for use in a living subject for purpose of repairing damaged tissues, methods of producing the skin substitutes and their uses. A biocomposite membrane comprising poly(ε-caprolactone) (PCL) and at least one material selected from collagen and gelatin is provided. In one embodiment, the biocomposite is a 2-component membrane of PCL and gelatin. In another embodiment, the biocomposite is a 3-component membrane of PCL, collagen and gelatin. The bio-composite membrane may be used directly in vivo as a wound dressing, or as a support for cell growth on each side of the membrane to produce an in vitro cultivated artificial skin for future in vivo and/or in vitro applications. | 2010-03-11 |
20100062042 | Methods, Systems and Devices for Administration of Chlorine Dioxide - Devices, compositions, systems and methods for the non-cytotoxic delivery of chlorine dioxide to a tissue. | 2010-03-11 |
20100062043 | Methods, Systems and Devices for Administration of Chlorine Dioxide - Devices, compositions, systems and methods for the non-cytotoxic delivery of chlorine dioxide to a tissue. | 2010-03-11 |
20100062044 | Method and a product to reduce and treat problems associated with tinea pedis - A ring-shaped toe-patch is provided for treatment and prevention of tinea pedis, commonly known as athlete's foot. The toe-patches are made of rubber-foam, attached to a hydrophobic material for elimination of fungus like | 2010-03-11 |
20100062045 | METHOD FOR SUPPRESSING COLORING OF ADHESIVE PREPARTION CONTAINING DONEPEZIL AND METHOD FOR REDUCING AMOUNTS OF DONEPEZIL-RELATED SUBSTANCES FORMED - [Object] By suppressing coloring of an adhesive preparation containing donepezil, a naturally colored appearance is realized. | 2010-03-11 |
20100062046 | POLYMORPHS OF NICOTINIC INTERMEDIATES - Crystalline forms of compounds (II), (III) and (IV) and processes to produce them are provided. | 2010-03-11 |
20100062047 | Composition for Administration to Mammals or Human - The invention relates to a composition for administration to mammals or humans, which is used to destroy damaged, pathogenic cells, including empty liposomes, structural protein elements and specific binding elements that are selected as a function of the pathogenic micro-organism or cell to be destroyed. When administered to the patient, the composition acts in the manner of an effective effector agent which interacts with the membrane of the target cell or with the membrane of the micro-organism in order produce discharge ports which release the intracellular content to the extracellular medium. | 2010-03-11 |
20100062048 | TOPICAL CO-ENZYME Q10 FORMULATIONS AND TREATMENT OF PAIN, FATIGUE AND WOUNDS - CoQ1O has a stimulatory effect on fibroblasts and keratinocytes, increases ATP production, decreases pain. The formulations are useful for promoting acute wound healing, fatigue and treatment of acute and chronic pain. | 2010-03-11 |
20100062049 | AQUEOUS FORMULATION FOR SELECTIVE TARGETING AND DELIVERING GENE TO CANCER CELLS - The present invention relates to a cationic lipid based aqueous formulation comprising cationic lipid, dexamethasone and a neutral co-lipid, wherein the said formulation is useful for selective targeting and delivering gene to glucocorticoid receptor expressing cancer cells. Glucorticoid receptors (GR) express in various normal and cancer cells. A lot of ligand activated physiological functions are known involving GR but its role in cancer progression (if any) is not clearly understood. Synthetic GR antagonist, dexamethasone (Dex) finds use as anti-inflammatory drug and is known to induce apoptosis in cancer cells. This Dex is included in a cationic lipid-based formulation as a co-lipid to deliver to and express genes specifically in cancer cells possibly through expressed GR. Gene delivery to cancer cells is independent of the gene construct, and tumor cell line. Normal transformed cells expressing GR but with no cancer lineage show much smaller level of transfection. The composition of the formulation is optimized. The formulation may have particular application to the enhanced delivery of anticancer genetic constructs to cancer, with the synergistic effect of Dex in inducing apoptosis as such. | 2010-03-11 |
20100062050 | MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS - This invention relates to a peptide or polypeptide (a) which is esterified or thio-esterified (i) at the carboxylate of the C-terminus with a guanidinium alkanol, a guanidinium alkanethiol, a PEG substituted with a guanidinium group and having a free hydroxyl group, or a PEG substituted with a guanidinium group and a sulthydryl group; (ii) at a side-chain carboxylate of one or more Asp or GIu residues, if present, with a guanidinium alkanol, a guanidinium alkanethiol, a PEG substituted with a guanidinium group and having a free hydroxyl group, or a PEG substituted with a guanidinium group and a sulfhydryl group; (iii) at a hydroxyl group of one or more Ser, Thr or Tyr residues, if present, with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group; (iv) at a sulthydryl group of one or more Cys residues, if present, with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group; and/or (v) at the N-terminus with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group, wherein said N-terminus is previously amidated with an alpha- or beta-hydroxy acid, and wherein the ester is formed between the hydroxy group of said alpha- or beta-hydroxy acid and the carboxylic group of said guanidinium alkanoic acid or said PEG substituted with a guanidinium group and a carboxyl group; and/or (b) which contains one or more disulfides, the disulfide being formed between the sulthydryl group of a Cys reside, if present, and a guanidinium alkanethiol or a PEG substituted with a guanidinium group and a sulthydryl group. | 2010-03-11 |
20100062051 | COMPOSITION FOR TREATMENT OF CERVIX CANCER - The present invention relates to a composition for the treatment of cervix cancer, more precisely a composition for the treatment of cervix cancer comprising the first active part containing human papilloma virus (referred as “HPV” hereinafter) specific siRNA as an active ingredient and the second active part containing an anticancer agent as an active ingredient. The composition for the treatment of cancer of the present invention has better anticancer effect than the single therapy of the HPV specific siRNA or the anticancer agent, and has an advantage of reducing side effects by using the anticancer agent at a low concentration. | 2010-03-11 |
20100062052 | PEPTIDE-BASED COMPOUNDS AS NEW INHIBITORS OF METALLOECTOPEPTIDASES, COMPOSITIONS COMPRISING SAID COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMETIC USES - The invention relates to a compound that inhibits a metallo-ectopeptidase, selected in the group consisting of x-aa2-aa1-z, x-aa3-aa2-aa1-z, x-aa4-aa3-aa2-aa1-z and x-aa5-aa4-aa3-aa2-aa1-z, wherein: aa1 and aa4, independently from each other, represent an arginine amino acid, an histidine amino acid, an asparagine amino acid or a lysine amino acid, aa2 represents a serine amino acid, a glycine amino acid, a threonine amino acid or an alanine amino acid, aa3 represents a phenylalanine amino acid, a leucine amino acid, an isoleucine amino acid, a tyrosine amino acid or a tryptophan amino acid, aa5 represents a glutamine amino acid, a glutamic acid amino acid, an asparagines amino-acid or a lysine amino acid, x and z, independently from each other, represent: —H; —OH1 SH; —a halogen atom, —an amino group, —an alkyl, haloalkyl or heteroalkyl group containing from 1 to 30 carbon atoms, linear or branched, —an alkenyl or alkynyl group containing from 2 to 30 carbon atoms, linear or branched, —a cycloalkyl, cycloakenyl, cycloalkynyl or an heterocyclic group containing from 3 to 30 carbon atoms, linear or branched, —one or more aryl or heteroaryl groups containing from 3 to 10 carbon atoms per cycle, —a alkoxy, thioalkyl, sulfonylalkyl, aminoalkyl containing from 1 to 30 carbon atoms, linear or branched, —one or more heterocyclic group, containing from 5 to 10 carbon atoms per cycle, said groups being optionally substituted by one or more halogen atoms, alkyl groups, hydroxy groups, alkoxy groups, aryloxy groups, acyloxy groups, carbamoyloxy groups, carboxy groups, mercapto groups, alkylthio groups, acylthio groups, arylthio groups, aryl groups, heterocyclic groups, heteroaryl groups or amino groups. | 2010-03-11 |
20100062053 | CHOLESTANOL DERIVATIVE FOR COMBINED USE - The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): | 2010-03-11 |
20100062054 | LIPOBEADS AND THEIR PRODUCTION - Lipobeads (liposome-encapsulated hydrogels) combine properties of hydrogels and liposomes to create systems that are sensitive to environmental conditions and respond to changes in those conditions in a fast time scale. Lipobeads may be produced by polymerizing anchored or unanchored hydrogels within liposomes or by mixing anchored or unanchored hydrogels with liposomes. Giant lipobeads may be produced by shrinking unanchored nanogels in lipobeads and fusing the resulting lipobead aggregates, long-term aging of anchored or unanchored lipobeads, or mixing anchored or unanchored aggregated nanogels with liposomes. Poly(acrylamide), poly(N-isopropylacrylamide), and poly(N-isopropylacrylamide-co-1-vinylimidazole) lipobeads were produced and characterized. | 2010-03-11 |
20100062055 | LIPID-BASED NITRIC OXIDE DONORS - Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula: | 2010-03-11 |
20100062056 | ENCAPSULATED PICOPLATIN - The invention provides an encapsulated unit dosage form for picoplatin that is adapted for oral administration of the picoplatin containing a substantially dry powder with about 20 to 55 wt % picoplatin in the physical form of a picoplatin particulate wherein an average picoplatin particle diameter is less than about 10 microns. The picoplatin particles are dispersed within the powder of the formulation which includes a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate and an effective amount of up to about 5 wt % of a lubricant. | 2010-03-11 |
20100062057 | Formulation - Novel capsules comprising a marine oil in an outer shell comprising alginate are disclosed. Also disclosed are methods of preparing the novel capsules and uses of thereof. | 2010-03-11 |
20100062058 | Delayed Release Formulations for Oral Administration of a Polypeptide Therapeutic Agent and Methods of Using Same - The invention provides compositions containing polypeptides, including therapeutic polypeptides such as interleukin-11, that are suitable for oral administration. | 2010-03-11 |
20100062059 | S-Nitrosothiols Containing Composition for the Treatment of Fatty Liver Diseases, Obesity and Other Diseases Associated with the Metabolic Syndrome and the Use of Such Compositions - The present invention refers to pharmaceutical compositions containing S-nitrosothiols as active principle. The referred compositions are intended for the treatment of the fatty liver disease and other diseases associated with the metabolic syndrome. The composition is administered either orally or rectally. | 2010-03-11 |
20100062060 | PHARMACEUTICAL COMPOSITION COMPRISING TRAMADOL AND KETOPROFEN IN ASSOCIATION - The present invention relates to a pharmaceutical composition comprising a combination of active principles. More specifically: a stable pharmaceutical composition comprising a combination of tramadol and ketoprofen. Furthermore, a combination in solid form in which the active principles are vehicled in pharmaceutical forms and/or products that prevent contact between them. Complementarily, the present invention also relates to the combined use of ketoprofen and tramadol in the preparation of an oral medicine useful for relieving pain as well as a method for relieving pain with an oral pharmaceutical composition comprising a combination of tramadol and ketoprofen. | 2010-03-11 |
20100062061 | Method For Making Cetirizine Tablets - In one aspect, the present invention features a method of producing a tablet including cetirizine including the steps of: (i) mixing cetirizine, a polyol, and a solvent for the cetirizine to form a cetirizine:polyol complex, wherein the solvent comprises water and an alkalizing agent and has a pH from about 2 to about 7; (ii) isolating particles of the cetirizine:polyol complex from the mixture; and (iii) forming the particles into a tablet. | 2010-03-11 |
20100062062 | Stabilized Coating for Pharmaceutical Formulations - A process is described for preparing stabilized tablet formulations for temperature and moisture sensitive active drugs. Water soluble polyvinyl alcohol is processed with drugs such as angiotensin converting enzyme (ACE) inhibitors and compressed into solid form once excess water is removed. Low dose polyvinyl alcohol ramipril tablets prepared by this process are stable under conditions of high humidity and heat for periods of at least up to six months with less than 8% hydrolysis of the prodrug to the active metabolite diketopiperazine (DKP). | 2010-03-11 |
20100062063 | LIGHT-STABLE SOLID PHARMACEUTICAL COMPOSITION OF RAMOSETRON - Provided is a preparation of ramosetron which is stable under irradiation with light. The solid pharmaceutical composition of the present invention can provide a stable preparation by blending a compound absorbing light having a specific wavelength with ramosetron which is unstable, usually under irradiation with light, or a pharmaceutically acceptable salt thereof. Particularly, this technique is useful because it is adaptable to a preparation containing ramosetron or a pharmaceutically acceptable salt thereof at a low content or an orally disintegrating tablet containing ramosetron or a pharmaceutically acceptable salt thereof. Also, the present invention relates to a method for stabilizing a solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof, which is characterized by blending a compound having characteristics of absorbing light having a specific wavelength. | 2010-03-11 |
20100062064 | Method for Delivering A Pharmaceutical Composition to Patient in Need Thereof - The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof | 2010-03-11 |
20100062065 | PHARMACEUTICAL COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM - Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a particular naphthoquinone-based compound, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient. | 2010-03-11 |
20100062066 | Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration - A pharmaceutical composition for the oral or parenteral administration of a compound of Formula (I) comprising an oil in water emulsion, wherein the oil phase comprises the free base of or a pharmaceutically acceptable salt thereof of a compound of Formula (I), and one or more surfactants which are soluble in the oil phase and/or the aqueous phase. The emulsion optionally contains one or more excipients that are soluble in the oil phase and/or the aqueous phase, such as pH modifying agents such as buffers, osmolality/tonicity modifying agents, emulsifying agents, water-soluble polymers, and preservatives. The compound of Formula (I) can be formulated as a solid material and stored until needed. Kits for forming the emulsion are provided. Prior to administration, the solid material can be reconstituted in an aqueous medium to form the emulsion. | 2010-03-11 |
20100062067 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT - A composition comprising lipid and surfactant, characterised in that the lipid and surfactant are in the form of macromolecular assemblies of less than 100 nm in diameter. The surfactant can have a HLB number of less than 20, or be an ether or ester surfactant, or be ionic. | 2010-03-11 |
20100062068 | CISTUS EXTRACTS - The present invention relates to the use of a nasal spray made from | 2010-03-11 |
20100062069 | PROCESS FOR PREPARING PARTICLES CONTAINING AN ANTIVIRAL - A process for preparing a particle comprising a co-precipitate surrounding a neutral hydrophilic carrier, said process comprising spraying an organic solution on a neutral hydrophilic carrier, said solution comprising at least one triazine or pyrimidine active ingredient having HIV inhibiting properties, one surface active agent, and one hydrophilic polymer, wherein the spraying of whole of the solution occurs in at least two separate steps, each of these steps followed by a grinding step of the product obtained at the end of the preceding step. | 2010-03-11 |
20100062070 | Pulverzed crystals of olmesartan medoxomil - An olmesartan medoxomil having a particle diameter at 90% cumulative volume of 75 μm or less, which provides an improved dissolution property. The olmesartan medoxomil is advantageously used to treat or prevent hypertension or a disease caused by hypertension. | 2010-03-11 |
20100062071 | Particle Formulations and Uses Thereof - Aqueous dispersions of chemically and physically stable particles for use in delivery of active pharmaceutical ingredients and processes for their production and use to enhance a biological response to an active pharmaceutical ingredient and prophylactically or therapeutically treat a subject are provided. Vaccines, wherein the active pharmaceutical ingredient is a solution of subunit vaccine antigen mixed with a colloidal dispersion of electrically charged particles and use of such vaccines in immunization are also provided. | 2010-03-11 |
20100062072 | Method for the delivery of a biologically active agent - A method of manufacturing a stable nanosuspension for delivery of a biologically active agent into the bloodstream of a subject is disclosed. A microfluidizable mixture is initially formed and processed via a microfluidization process to form the stable nanosuspension, which may be administered via the buccal mucosa or other suitable routes of administration. This product demonstrates increased bioavailability, enhanced period of onset, and enhanced stability for a controlled-release product. | 2010-03-11 |
20100062073 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES COMPRISING ENTERIC POLYMERS CASEIN - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and an enteric polymer, and casein. | 2010-03-11 |
20100062074 | ALLERGEN INACTIVATING AGENT - An allergen inactivating agent for preventing allergic manifestations or alleviating symptoms by reducing antigenicity of an allergen through contact with the allergen includes dissolved chlorine dioxide as an active ingredient. | 2010-03-11 |
20100062075 | Germicidal coating on hand held remote control devices for controlling electrical and electronic devices - The current invention addresses an issue where hand held remote control devices and other consumer electronics products can become a carrier of infectious germs or bacteria once touched by a person or animal carrying a pathogen or infectious agent. School aged children and house hold pets may be the carrier of such pathogens. Adults or any other person inflicted with a common illness such as a cold or flu can infect a hand held remote or other consumer electronic product which in turn can transmit those germs to the next person or persons who handle the remote. The present invention is intended to minimize the effects of pathogen transmission from person to person by killing the pathogens once they are deposited on such a consumer electronic product. | 2010-03-11 |
20100062076 | Non-Cytotoxic Chlorine Dioxide Fluids - Disclosed are compositions related to a substantially non-cytotoxic chlorine dioxide solution. The solution may be a thickened fluid composition. Also disclosed are methods of making and using a substantially non-cytotoxic thickened fluid compositions or solutions comprising chlorine dioxide solution. An oxidizing composition of reduced irritation is also disclosed. | 2010-03-11 |
20100062077 | PYRROLO[1,2-A]IMIDAZOLEDIONE EFFECTIVE IN THE TREATMENT OF PERIPHERAL NEUROTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS - The use of a compound of formula (I), is disclosed in treating and/or preventing 5 chemotherapy-induced peripheral neurotoxicity (CIPN). The invention includes pharmaceutical compositions wherein the compound of formula (I) is present in a mixture with anticancer agents. An improved anticancer treatment with reduced CIPN-related side effects is also provided. | 2010-03-11 |
20100062078 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND THE SIGNALING PATHWAY THEREOF - A pharmaceutical composition, composed of protoapigenone (formula I), for treating gynecological cancers, prostate cancer, urinary bladder cancer and hepatocarcinoma is provided. Protoapigenone has cytotoxicity on these cancers, and arrests the cell cycle at S and G2/M phases. In addition, protoapigenone regulates cell signaling pathways, such as caspase-3, PARP, p-38 MAPK and JNK½, to induce apoptosis. Protoapigenone significantly inhibits the xenograft tumor growth on nude mice, without major side effects. Co-treatment o protoapigenone of protoapigenone and cisplatin shows synergistic cytotoxicity of MDAH-2774 ovarian cancer cells. | 2010-03-11 |
20100062079 | POLYMORPHISMS PREDICTIVE OF PLATINUM-COORDINATING COMPLEX INDUCED OTOTOXICITY - Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of ototoxicity in response to receiving one or more platinum-coordinating compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of ototoxicity. | 2010-03-11 |
20100062080 | Elemental indium and indium compounds suitable for human, mammal, fowl and reptilian nutrition - This patent relates to the use of safe forms of pure elemental indium and associated compounds approximately ¼ to 1 mg. per 50 pounds of body weight in a water-soluble liquid solution taken away from other foods orally into the mouth and stomach to enhance human, mammal, fowl, and reptile nutrition and metabolism. This use of indium may be the greatest nutritional discovery of the 21st century, raising human and mammal DNA glandular powers to new heights of performance and anti-aging disease resistance formerly thought unattainable. This is especially important at this stage of evolution to advance human mentality and gland functions to better deal with the over-stimulation of expanding informations, moral choices, increased pollutants, and stresses of modern society. | 2010-03-11 |
20100062081 | Use of tellurium containing compounds as nerve protecting agents - A novel neuroprotective agent is disclosed for the treatment and prevention of neurodegenerative disorders which is based on the administration of an effective amount of a tellurium compound which has a specific ability to induce the differentiation and interfere with apoptotic cell death pathways of neuronal PC-12 cells. | 2010-03-11 |
20100062082 | ION SENSOR FOR FLUID AND METHOD FOR ITS MANUFACTURE - The invention provides a method for the measurement of a concentration of a charged species in a sample, the sample having a plurality of types of charged species and at least one insoluble component. The method comprises: providing the sample on a surface of a partly permeable layer ( | 2010-03-11 |
20100062083 | DERMAL FILM-FORMING LIQUID FORMULATIONS FOR DRUG RELEASE TO SKIN - The present invention is directed to liquid compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, forming a dermal film after application onto the skin, useful for delivery of actives onto the skin surface and in the stratum corneum. | 2010-03-11 |
20100062084 | Treatment Of Gastrointestinal Diseases - The present invention relates to compositions (including medicaments and nutritional products) for use in the prevention or treatment of gastrointestinal disease. Such compositions comprise a therapeutically effective amount of a less than or equal to 4 kDa soluble fraction derivable from potato juice. | 2010-03-11 |
20100062085 | TREATMENT OF DAMAGED SKIN - A medicament for treating skin is described. It comprises essentially of | 2010-03-11 |
20100062086 | Compositions and Methods of Their Use for Improving the Condition and Appearance of Skin - The present invention relates to compositions and methods for treating, preventing and improving the condition and aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include natural plant constituents, or synthetic equivalents thereof, which inhibit or decrease expression of C-reactive protein expression, production or secretion, thereby reducing, inhibiting, or ameliorating dermatological signs of aging. The compositions of the invention may be topically applied to the skin, or are delivered by directed means to a site in need thereof, in an amount effective in improving the condition and aesthetic appearance of skin. | 2010-03-11 |
20100062087 | Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing - In an embodiment of the present invention, a nutraceutical formula comprising a combination of two or more substances from the group: berry extract, chromium, zinc, trans-resveratrol, l-arginine, chlorophyll, vitamin C and aloe vera combined synergistically to reduce inflammation in mammals suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a combination of two or more substances from the group: berry extract, chromium, zinc, fr-απs-resveratrol, l-arginine, chlorophyll, vitamin C and aloe vera combined synergistically to enhance wound healing in mammals suffering from diabetes. In an alternative embodiment of the present invention, a nutraceutical formula comprising a combination of two or more substances from the group: berry extract, chromium, zinc, trans-resveratrol, l-arginine, chlorophyll, vitamin C and aloe vera combined synergistically to reduce inflammation in mammals not suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a combination of two or more substances from the group: berry extract, chromium, zinc, trans-resveratrol, l-arginine, chlorophyll, vitamin C and aloe vera, combined synergistically to enhance wound healing in mammals not suffering from diabetes. | 2010-03-11 |
20100062088 | COMPOSITIONS COMPRISING KAKADU PLUM EXTRACT OR ACAI BERRY EXTRACT - A topical skin care composition comprising kakadu plum extract or acai berry extract, or a combination of both, is disclosed. The composition can include a high oxygen radical absorbance capacity (ORAC) value. The composition can improve the skin's visual appearance, physiological functions, clinical properties, and/or biophysical properties. | 2010-03-11 |
20100062089 | AMELIORATING OR PROPHYLACTIC AGENT FOR METABOLIC SYNDROME, AND BEVERAGE, FOOD AND FEED EACH COMPRISING THE SAME - The present invention provides an ameliorative or preventive agent for metabolic syndrome comprising a barley bran or an α-amylase-treated product thereof as an active ingredient. The present invention also provides an ameliorative or preventive agent for metabolic syndrome comprising a water-insoluble component of an α-amylase-treated product of a barley bran as an active ingredient. These are naturally derived ameliorative or preventive agents for metabolic syndrome which can inhibit the accumulation of visceral fat to ameliorate or prevent metabolic syndrome. | 2010-03-11 |
20100062090 | Pharmaceutical Composition Comprising Metadoxine and Garlic Oil For Preventing and Treating Alcohol-Induced Fatty Liver and Steatohepatitis - Provided is a pharmaceutical or food or drink composition for preventing or treating alcohol-induced fatty liver or steatohepatitis comprising metadoxine (pyridoxol 1-2-pyrrolidone-5-carboxylate) and garlic oil as active ingredients. The concurrent administration of metadoxine and garlic oil according to the present invention exhibits outstandingly superior effects of inhibiting the accumulation of triglyceride and increase of blood AST (aspartate aminotransferase) level in liver el tissue, inhibiting the expression of FAS (fatty acid synthase), CYP2E1 and iNOS (inducible nitric oxide synthase) and inhibiting the deactivation of AMPK (AMP-activated protein kinase), as compared to the administration of metadoxine or garlic oil only. | 2010-03-11 |
20100062091 | PROCESSED PRODUCT OF FENUGREEK SEEDS AND METHOD FOR PRODUCING THE SAME - It is an object of the present invention to enhance the α-amylase inhibitory activity of a fenugreek seed component. According to the present invention, the bitter taste of fenugreek seeds can be collaterally reduced. | 2010-03-11 |
20100062092 | METAL MOLD FOR COMPRESSION FORMING - [Problem] To provide a metal mold for forming a preform decreasing the hitting of metal molds at a portion where a slide insert metal mold and a cavity metal mold undergo the sliding yet maintaining the pressure. | 2010-03-11 |
20100062093 | METHOD AND APPARATUS FOR PRODUCING FULLY COOKED EXTRUDATES WITH SIGNIFICANTLY REDUCED SPECIFIC MECHANICAL ENERGY INPUTS - Improved extruders and methods for the extrusion cooking of comestible products such as human foods or animal feeds are provided wherein the products may be produced with very low specific mechanical energy (SME) inputs as compared with conventional processing. The methods preferably involve introduction of very high levels of steam into the extruder barrel ( | 2010-03-11 |
20100062094 | GAS HYDRATE COMPRESSION MOLDING MACHINE - A molding machine for production of gas hydrate pellets under a high pressure in gas hydrate forming conditions, which is inexpensive through minimizing of the use of expensive mechanical seal. The molding machine comprises two forming rolls each fitted to a rotary shaft whose both ends are supported by bearings; a drive unit for rotating the forming rolls; a screw transfer unit for supplying powder to the forming rolls; and a high-pressure vessel, wherein the bearings, the rotary shaft and the forming rolls are all disposed in the high-pressure vessel. | 2010-03-11 |
20100062095 | COUPLING FOR A PLASTICS INJECTION MOLDING MACHINE - A coupling for a plastics injection molding machine which connects a drive shaft to a screw comprises at least one force sensor with a measuring element for the indirect determination of the nozzle pressure. The coupling comprises a first connection which has torsional strength and does not transfer axial force. The coupling comprises a second connection, which is mechanically uncoupled from the first connection and is compression proof and does not transfer torque between the drive shaft and the feed screw. The measuring element is arranged in the force path A of the second compression proof connection but is not also in the force path T of the first connection. Thus, during operation, measurements in the measuring element are not falsified by torsional forces. | 2010-03-11 |
20100062096 | AEROSOL CONTAINER - An aerosol container ( | 2010-03-11 |
20100062097 | SHEET OR FILM CLIPPING STRETCHER - A clip support member | 2010-03-11 |
20100062098 | STAMPER FOR MINUTE STRUCTURE TRANSFER AND A METHOD FOR MANUFACTURING THE SAME - The present invention can provide a stamper for minute structure transfer to be excellent in durability. The present invention is characterized by which a minute pattern as formed in one side of a substrate comes in contact with a material to be transferred and the minute pattern is transferred on a resin layer of a surface of the material to be transferred. At least one layer of a thin film is mounted on at least one side of both surfaces of the substrate, the substrate and the thin film are different in a coefficient of linear expansion each other, and the substrate is curved to swell up to be convex in the side of the minute pattern by an internal stress generated in the thin film. | 2010-03-11 |
20100062099 | MOLDING TOOL FOR ORIGINAL SHAPING OR RESHAPING OF COMPONENTS COMPOSED OF MATERIALS THAT CAN BE THERMALLY INFLUENCED - The invention relates to a molding tool for the production of components composed of fiber composite materials, in which the molding tool has a fiber composite structure and an electrical resistance heating element, whereby carbon fibers or carbon filaments are embedded into the fiber composite structure of the molding tool in a plastic matrix, close to the shaping surface of the molding tool. Such a molding tool is further developed in that the carbon fibers or carbon filaments in the plastic matrix, close to the shaping surface, essentially determine the mechanical strength of the molding tool, and that the electrical resistance heating element is interconnected in such a manner that at least individual sections of the electrical resistance heating element form an electrical parallel circuit with one another. | 2010-03-11 |
20100062100 | Nozzle Shutoff for an Injection Molding Machine - The present invention is directed to an injection molding valve configured to prevent the leaking or stringing of injected thermoplastic from the valve. The valve includes a housing having a first bore along a length thereof and a second bore intersecting the first bore. A rotatable member is inserted through the second bore and is in communication with a lever for the actuation thereof. The rotatable member includes a hole therethrough such that when the hole is aligned with the first bore, thermoplastic may travel freely through the first bore. The second bore further includes at least one groove in communication with a port for receiving injected thermoplastic. The injected thermoplastic is hardened to form an seal therein and configured to prevent thermoplastic from leaking out of the valve housing. | 2010-03-11 |
20100062101 | COMPOSITIONS - A fat continuous confectionery composition comprises less than 2% by weight of a fermentable sugar, and a sweetening component in an amount of at least 25% by weight of the composition. The sweetening component comprises at least 50% by weight non-hydrogenated isomaltulose and may also comprise at least 5% by weight inulin, dextrin or a mixture of inulin and dextrin. The composition may comprise milk or whey protein in an amount of between 1 and 10% by weight of the composition. | 2010-03-11 |
20100062102 | METHOD TO PRODUCE CHICKENS - A method for producing broiler chickens comprising feeding to the chickens a chicken feed comprising from 10 | 2010-03-11 |
20100062103 | Method For Improving The Quality Of Meat By Reducing Boar Taint - Disclosed is a method for reducing boar taint in pigs, said method comprising injecting a solution of a pharmaceutically acceptable zinc salt into a dorsal cranial portion of each testis of a male pig preferably when the pig is less than one week old. The solution contains at least 20 mg of zinc ion per ml of solution and the solution is injected into the testis in a volume that is contained within the testis. | 2010-03-11 |
20100062104 | METHOD FOR FILTERING BEER - A method for filtering beer, wherein the beer to be produced is guided into a filter. For the improvement of the filtering output, the beer to be produced is subjected to a shaking process before being introduced into the filter. | 2010-03-11 |
20100062105 | METHOD OF PREPARING A CAKE USING PHOSPHOLIPASE - The quality of a cake quality may deteriorate if the amount of eggs in the recipe is reduced. This deterioration can be counteracted by adding a phospholipase to the cake batter, as seen by an increased cake volume and improved cake properties after storage, e.g. increased cohesiveness, increased springiness, and increased elasticity. The cake quality (as measured by these parameters) can be further improved, even up to the level of the original cake, by adding a non-egg protein together with the phospholipase. Accordingly, a cake is prepared by a method, comprising: a) preparing a cake batter by mixing cake batter ingredients, said ingredients comprising non-phospholipase treated egg lecithin and phospholipase, and b) baking the cake batter to make the cake. | 2010-03-11 |
20100062106 | NOVEL METHOD TO PRODUCE CAKE - The invention relates to a novel use of a phospholipase A in the production of cake to improve at least one of the properties selected from the group consisting of: (i) batter viscosity, (ii) specific density, (iii) initial crumb softness, (iv) crumb pore homogeneity, (v) crumb pore diameter, (vi) crumb softness upon storage, (vii) shelf life and/or (viii) cake volume. The invention also relates to a novel use of phospholipase A in the production of cake to enable reduction of the amount of eggs and/or fat used in the recipe. | 2010-03-11 |
20100062107 | GLYCERIDE OIL COMPOSITION FROM FISH OIL AND PREPARATION METHOD THEREOF - Provided are a glyceride oil composition derived from a fish oil and a preparation method thereof. The composition includes docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) with a content of 45 to 95% by weight and eicosapentaenoic acid (EPA) with a content of 0.001 to 13% by weight among constituent fatty acids, and a saturated fatty acid having 16 to 18 carbon atoms, which is bonded at 1- and 3-positions, with a content of 0.001 to 5% by weight among constituent fatty acids, in which a weight ratio of docosahexaenoic acid (DHA)/docosapentaenoic acid (DPA) is 0.5 to 8 and a weight ratio of docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) is 3.5 to 15. The glyceride oil composition derived from fish oil has nutritional and physiological superiority due to containing a great amount of polyunsaturated fatty acids such as DHA and DPA in a form of glyceride, and can minimize disadvantages of EPA such as inhibition of ω-6 fatty acid metabolism by containing a low amount of EPA. The glyceride oil composition is excellent in digestion and absorption of polyunsaturated fatty acids into a human body by containing a low amount of saturated fatty acids at 1- and 3-positions and process characteristics such as an oxidation stability and water-dispersibility. | 2010-03-11 |
20100062108 | PROCESS FOR PRODUCTION OF FERMENTED MILK, AND FERMENTED MILK - Fermented milk having a satisfactory level of hardness as well as smooth texture produced by deoxidizing (deaerating) a yogurt mix, subjecting the deoxidized (deaerated) product to an UHT processing, and then fermenting the resulting product. A process for producing a fermented milk includes a first deoxygenating step for decreasing oxygen concentration in a yogurt mix; a ultra high temperature sterilization step for heating the yogurt mix after the first deoxygenating step for longer than 1 second at higher than 110 degrees Celsius so as to sterilize the yogurt mix; and a fermentation step for fermenting the yogurt mix after the ultra high temperature sterilization step. | 2010-03-11 |
20100062109 | ENZYMATIC METHODS OF FLAVOR MODIFICATION - Described are enzymatic methods of making food products and modifying food flavor using, for example, a lipase and a lactase, and related enzyme compositions and food products. | 2010-03-11 |
20100062110 | In-Line Continuous Flow Process for Making Cheese - The invention provides a novel process of making cheese including a quick and efficient coagulation step forming discrete form and uniform curd particles in an in-line continuous flow process, separation of the curd particles from the whey and subsequent processing to produce a desired soft, semi-soft, hard or extra hard cheese. | 2010-03-11 |
20100062111 | PUFFED PET TREAT - An animal protein-based dog treat has a soft crunch and a stable shelf life without use of an appreciable amount of sodium or chemical preservatives. A method of producing the dog treat entails use of extrusion and heating processes to trap moisture in the interior of the dog treat, and then to expand and evaporate the moisture. This process creates in an internal portion of the dog treat voids or air pockets that provide desired texture and strength characteristics. | 2010-03-11 |